Yu Eun-Mi, Kittai Adam, Tabbara Imad A
Department of Hematology/ Oncology, George Washington University, Washington, DC, U.S.A.
Department of Internal Medicine, George Washington University, Washington, DC, U.S.A.
Anticancer Res. 2015 Oct;35(10):5149-65.
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, and while in early, asymptomatic stages treatment is not indicated, the threat to the quality of life and increased mortality of patients posed by more advanced-stage disease necessitate therapeutic intervention. Guidelines of when and how to treat are not well-established because CLL is a disease of the elderly and it is important to balance preservation of functional status and control of the disease. Advances in molecular and genetic profiling has led to the ability to identify sub-groups of patients with CLL whose disease may respond to selected therapy. This review discusses current standard therapies in the major sub-groups of CLL based on age and functional status, in both the front-line and relapsed/refractory settings. It also provides a concise review of novel agents that have shown considerable efficacy in CLL.
慢性淋巴细胞白血病（CLL）是成人中最常见的白血病类型。虽然在早期无症状阶段不需要进行治疗，但疾病进展期对患者生活质量的威胁以及死亡率的增加使得治疗干预成为必要。由于CLL是一种老年疾病，并且在保持功能状态和控制疾病之间取得平衡很重要，因此关于何时以及如何治疗的指南尚未完全确立。分子和基因谱分析的进展使得能够识别CLL患者的亚组，这些患者的疾病可能对特定治疗有反应。本综述讨论了基于年龄和功能状态的CLL主要亚组在一线和复发/难治性情况下的当前标准疗法。它还简要回顾了在CLL中显示出显著疗效的新型药物。
